Discovery of pyrazolo[3,4-]pyrimidine and pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations

• Published in: RSC advances 2022-05, Vol.12 (23), p.14865-14882
• Main Authors: Nassar, Ibrahim F, Abdel Aal, Mohammed T, El-Sayed, Wael A, E Shahin, Mahmoud, Elsakka, Elsayed G. E, Mokhtar, Mahmoud Mohamed, Hegazy, Maghawry, Hagras, Mohamed, Mandour, Asmaa A, Ismail, Nasser S. M
• Format: Article
• Language: English
• Subjects: Anticancer properties; Apoptosis; Cell cycle; Chemical synthesis; Chemistry; Cytotoxicity; Hydrogen bonding; Molecular docking
• ISSN: 2046-2069; 2046-2069
• DOI: 10.1039/d2ra01968j

CDK2 inhibition is an appealing target for cancer treatment that targets tumor cells in a selective manner. A new set of small molecules featuring the privileged pyrazolo[3,4- d ]pyrimidine and pyrazolo[4,3- e ][1,2,4]triazolo[1,5- c ]pyrimidine scaffolds ( 4-13 ) as well as the thioglycoside derivatives ( 14 , 15 ) were designed, and synthesized as novel CDK2 targeting compounds. The growth of the three examined cell lines was significantly inhibited by most of the prepared compounds. Results revealed that most of the compounds showed superior cytotoxic activities against MCF-7 and HCT-116 with IC 50 range (45-97 nM) and (6-99 nM), respectively, and moderate activity against HepG-2 with IC 50 range of (48-90 nM) compared to sorafenib (IC 50 : 144, 176 and 19 nM, respectively). Of these compounds, 14 & 15 showed the best cytotoxic activities against the three cell lines with IC 50 values of 45, 6, and 48 nM and 46, 7, and 48 nM against MCF-7, HCT-116 and HepG-2, respectively. Enzymatic inhibitory activity against CDK2/cyclin A2 was achieved for the most potent anti-proliferative compounds. Compounds 14 , 13 and 15 revealed the most significant inhibitory activity with IC 50 values of 0.057 ± 0.003, 0.081 ± 0.004 and 0.119 ± 0.007 μM, respectively compared to sorafenib (0.184 ± 0.01 μM). Compound 14 displayed potent dual activity against the examined cell lines and CDK2, and was thus selected for further investigations. It exerted a significance alteration in cell cycle progression, in addition to apoptosis induction within HCT cells. Molecular docking simulation of the designed compounds confirmed the good fit into the CDK2 active site through the essential hydrogen bonding with Leu83. In silico ADMET studies and drug-likeness studies using a Boiled Egg chart showed suitable pharmacokinetic properties which helped in structure requirement prediction for the observed antitumor activity. A new set of pyrazolo[3,4- d ]pyrimidine and pyrazolo[4,3- e ][1,2,4]triazolo[1,5- c ]pyrimidine scaffolds ( 4-13 ) as well as the thioglycoside derivatives ( 14 , 15 ) were designed, and synthesized as novel CDK2 targeting compounds.